The short answer
Pemvidutide is a dual agonist of the GLP-1 and glucagon receptors. Browne and colleagues published a randomised controlled trial of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease in JHEP Reports in November 2025.
Key facts
- Class
- GLP-1 / glucagon dual agonist
- Trial duration
- 24 weeks
- Condition studied
- MASLD
- Published
- JHEP Rep, November 2025 (PMID 41113119)
- Design
- Randomised, controlled
- Same receptor pair as
- Survodutide, mazdutide
- Authorisation
- None
Why glucagon agonism points at the liver
Glucagon receptor activation increases energy expenditure and mobilises hepatic fat. That second effect is what makes a GLP-1/glucagon dual agonist a liver compound as much as a weight compound, it acts directly on the tissue where steatotic liver disease begins, rather than only reducing the adiposity upstream of it.
Why the liver indication is pursued so hard in this class
Because the mechanism suits it and because the need is substantial. Survodutide and mazdutide share the receptor pair and have both been studied with hepatic endpoints in view. A compound whose glucagon arm mobilises liver fat is being aimed at the organ that arm acts on, which is a more direct rationale than most indication expansion in this field.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
MASLD and MASH are not the same endpoint
Metabolic dysfunction-associated steatotic liver disease covers fat accumulation; steatohepatitis adds inflammation and cell injury. Trials in the two report different things, and the published trial here names MASLD. Reading a steatosis result as though it were a steatohepatitis result overstates it, and the terms are close enough to be conflated easily.
Why 24 weeks fits a liver endpoint better than a weight one
Hepatic fat responds relatively quickly and can be measured by imaging rather than requiring biopsy. Twenty-four weeks is short for a weight-reduction trial and reasonable for a change in liver fat content, which is one reason liver programmes can read out sooner than the histological endpoints described elsewhere on this site.
The glucagon trade-off
Glucagon raises blood glucose, which is why glucagon receptor agonism only works alongside sufficient GLP-1 activity to offset it. The balance between the two arms is the central design parameter, and it is fixed at the molecule level. The same constraint retatrutide faces with its third receptor.
Regulatory position
Pemvidutide holds no marketing authorisation anywhere and is investigational. Nothing supplied on this site is related to it or is an alternative to any treatment for liver disease.
Frequently asked questions
What does pemvidutide target?
The GLP-1 and glucagon receptors, the same pair as survodutide and mazdutide.
Why is it studied in liver disease?
Glucagon receptor agonism mobilises hepatic fat, so the mechanism acts directly on the tissue where steatotic liver disease begins.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBrowne SK et al., Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: a randomized, controlled clinical trial. JHEP Rep 2025 (PMID 41113119)pubmed.ncbi.nlm.nih.gov
- PubMedSantos Solis R et al., Efficacy and safety of dual and triple GLP-1-based polyagonists in MASLD and steatohepatitis. Cureus 2026 (PMID 42529769)pubmed.ncbi.nlm.nih.gov
- PubMedSanyal AJ et al., Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. NEJM 2025 (PMID 40305708)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- An Amylin Analogue Built to Stand AlonePetrelintide is described as a potent, stable, long-acting human amylin analogue - engineered by Zealand Pharma with Boehringer Ingelheim.
- The Amyloid Problem at the Centre of Amylin DesignHuman amylin forms amyloid fibrils. Every amylin medicine is a solution to that, and the two available solutions are instructively different.
- The Class's Defining Safety PropertyGLP-1 amplifies insulin secretion only when glucose is already elevated. Below that threshold the signal does almost nothing - which is the whole point.
- Forcing the Channel Shut Regardless of GlucoseSulfonylureas close the beta cell's potassium channel directly, bypassing the glucose sensing step. That is precisely why they cause hypoglycaemia.
- The Number Depends on Three Things Before the DrugBackground therapy, the glucose threshold used, and how much HbA1c fell all move a hypoglycaemia figure. The compound is often the smallest factor.